Rheumatoid Arthritis-Associated Ild
TNF inhibitors do not increase adverse event risk in rheumatoid arthritis-associated ILD
Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with rheumatoid arthritis-associated interstitial lung disease, according to data published in The Lancet Rheumatology.
Short telomeres associated with prevalent ILD in rheumatoid arthritis
Short telomeres were strongly associated with prevalent interstitial lung disease among patients with rheumatoid arthritis, according to cross-sectional study results published in Respiratory Medicine.
One-third of patients with rheumatoid arthritis-associated ILD experience acute exacerbation
The incidence of acute exacerbation was nearly one-third in patients with rheumatoid arthritis-associated interstitial lung disease, researchers reported in Chest.
VIDEO: Suspected RA, lung disease associations explored at ACR
Jeffrey A. Sparks, MD, MMSc, speaks with Healio about a presentation from ACR Convergence 2021 that reported predictors of mortality based on both rheumatoid arthritis and lung characteristics.
Dual autoantibody seropositivity may increase risk for prevalent rheumatoid arthritis-ILD
Combined rheumatoid factor and anti-citrullinated protein antibody seropositivity was strongly associated with prevalent rheumatoid arthritis-associated interstitial lung disease in a cohort of U.S. veterans, researchers reported.
Methotrexate does not increase risk for rheumatoid arthritis-associated ILD
Methotrexate use by patients with rheumatoid arthritis was not associated with an increased risk for developing interstitial lung disease, according to a study published in European Respiratory Journal.